6 October 2025 – Sydney, Australia | LTR Pharma Limited (ASX:LTP) has increased its ownership in LevOmega Pty Ltd from 33% to ~43% via a strategic $1 million investment. The additional stake was acquired via the Company’s wholly-owned subsidiary, LTR Spectrum Pty Ltd, and follows LevOmega’s successful capital raising to progress its research and development programs.
LevOmega, originally co-founded by LTR Pharma, Levur Pty Ltd and Green Blue Health Pty Ltd, is developing sustainable, pharmaceutical-grade omega-3 products with a proprietary platform. This investment is aimed at accelerating technical validation, pilot production, and commercialisation of LevOmega’s nature-identical omega-3 ingredients.
The decision comes at a time where global demand for omega-3 oils is growing due to their cardiovascular and anti-inflammatory health benefits. Traditional sources such as fish oil face increasing challenges caused by overfishing, pollution, and declining ocean yields. As marine-derived omega-3 supply becomes less reliable, more scalable and sustainable alternatives like that of LevOmega are expected to become increasingly important.
LTR Pharma Executive Chairman, Lee Rodne, said: “We are delighted to deepen our commitment to LevOmega. This investment not only increases our equity stake to ~43% but also provides LevOmega with the resources to accelerate development of pharmaceutical-grade omega-3 products at a time when traditional fish oil supply chains are under increasing pressure from overfishing, pollution, and declining ocean yields.
For LTR Pharma, this investment underscores our ability to identify and support scalable, first-in-class solutions that address global sustainability challenges while remaining highly complementary to our core intranasal pharmaceutical pipeline.”
This investment forms part of LTR Pharma’s broader strategy to build a portfolio of innovative, first-in-class solutions that target large, global unmet medical and health needs.
About us:
About LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.
LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]